Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer (NEOPAX-001)
Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Sponsor: Celgene Corporation
This EARLY_PHASE1 trial investigates Pancreatic Adenocarcinoma Locally Advanced and Pancreatic Adenocarcinoma Metastatic and is currently completed. Celgene Corporation leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Completed EARLY_PHASE1
Status: Unknown Status → Completed
-
Feb 2017 — Oct 2020 [monthly]
Unknown Status EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status Phase 0
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- Jean-Luc Van Laethem
For direct contact, visit the study record on ClinicalTrials.gov .